Home > Insider Trading > Filing (0000950170-23-068370)

Filing Details

Accession Number:: 0000950170-23-068370
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-12-05 18:58:49
Reporting Period:: 2023-12-01

Accepted Time:: 2023-12-05 18:58:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1088856	Corcept Therapeutics Inc	CORT	Pharmaceutical Preparations (2834)	770487658

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1698310	Sean Maduck	C/O Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park CA 94025	See Remarks	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-12-01	10,009	$2.61	83,300	No	4	M	Direct
Common Stock	Acquisiton	2023-12-01	14,991	$3.29	98,291	No	4	M	Direct
Common Stock	Disposition	2023-12-01	25,000	$25.56	73,291	No	4	S	Direct
Common Stock	Acquisiton	2023-12-01	582	$25.97	73,873	No	4	A	Direct
Common Stock	Acquisiton	2023-12-01	582	$0.00	74,455	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	A	Direct
No	4	A	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2023-12-01	10,009	$0.00	10,009	$2.61
Common Stock	Stock option (right to buy)	Disposition	2023-12-01	14,991	$0.00	14,991	$3.29

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,000		2024-08-07	No	4	M	Direct
16,986		2025-02-18	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	10,000	Indirect	See Footnote
Common Stock	10,000	Indirect	See Footnote

Footnotes

Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.47 to $25.785. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics 2012 Incentive Award Plan on December 1, 2023.
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
Fully exercisable.